TITLE

Research Into Rare Diseases of Childhood

AUTHOR(S)
Batshaw, Mark L.; Groft, Stephen C.; Krischer, Jeffrey P.
PUB. DATE
May 2014
SOURCE
JAMA: Journal of the American Medical Association;5/7/2014, Vol. 311 Issue 17, p1729
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
The article focuses on clinical research into rare diseases in children. The role of the Orphan Drug Act of 1983 in the prevalence of clinical trials dealing with rare diseases is discussed. The objectives of the Rare Diseases Clinical Research Network (RDCRN) set up by the U.S. National Institutes of Health (NIH) are enumerated, including the promotion of proof-of concept clinical research projects. Information on the Urea Cycle Disorders Consortium (UCDC) of the RDCRN is presented.
ACCESSION #
95902550

 

Related Articles

  • Research Into Rare Diseases of Childhood. Batshaw, Mark L.; Groft, Stephen C.; Krischer, Jeffrey P. // JAMA: Journal of the American Medical Association;4/30/2014, Vol. 311 Issue 17, p1729 

    The authors express their views on research related to rare diseases of childhood in the U.S. released as of April 2014. Topics discussed include the impact of the Orphan Drug Act on the acceleration of clinical trials, the support expressed by the National Institutes of Health (NIH) for such...

  • NIH to roll out undiagnosed diseases program.  // Diagnostics & Imaging Week;5/22/2008, Vol. 11 Issue 21, p2 

    The article offers information on the Undiagnosed Diseases Program (UDP) of the U.S. National Institutes of Health (NIH), announced by NIH director Elias Zerhouni and other senior members of NIH. According to Zerhouni, the goal of the UDP is to improve disease management and to advance medical...

  • NIH faces marching orders on orphan drug shortage. Dolgin, Elie // Nature Medicine;May2011, Vol. 17 Issue 5, p522 

    The article reports on the shortage of the orphan drug Fabrazyme, which forced people to petition the U.S. National Institutes of Health (NIH) to intervene. It mentions that people with Fabry's disease have faced serious deficits of the drug when manufacturer Genzyme Corp. ceased the operation...

  • Depression.  // World Almanac & Book of Facts;2009, p696 

    An encyclopedia entry for the term "depression" is presented. It refers to a serious illness that affects thoughts, feelings, and the ability to function in daily life. It is estimated that 19 million Americans suffer from depression in any given year, according to the National Institutes of...

  • Hearing Loss Is Twice as Common in People with Diabetes.  // Hearing Review;Aug2008, Vol. 15 Issue 9, p50 

    The article discusses research on the prevalence of hearing loss in adults with diabetes. It references a study by K. E. Bainbridge, H. J. Hoffman and C. C. Cowie that was funded by the National Institutes of Health (NIH) and published early online June 17, 2008, in the "Annals of Internal...

  • Teams will use latest tools to investigate undiagnosed diseases. Roehr, Bob // BMJ: British Medical Journal (International Edition);5/24/2008, Vol. 336 Issue 7654, p1149 

    The article reports on a unique program which has been developed by the U.S. National Institutes of Health. The program, which will offer the latest advances in tools and medical information, will allow patients who have signs and symptoms that doctors have not been able to give a diagnosis for,...

  • Legal and Regulatory Update.  // Journal of Commercial Biotechnology;Oct2009, Vol. 15 Issue 4, p360 

    The article offers world news briefs related to pharmaceutical industry. On February 11, 2009, a judgment is handed down regarding the patents of two families on radioactive imaging Myoview. The European Patent Office (EPO) announced that effective 2010, the agency will implement measures to...

  • Genetic Alliance Issues Statement Applauding New NIH Therapeutics for Rare and Neglected Diseases Program.  // Ascribe Newswire: Medicine;5/20/2009, p5 

    The article presents comments of Sharon Terry, president and chief executive officer of Genetic Alliance, a nonprofit health advocacy organization, on the launch of the Therapeutics for Rare and Neglected Diseases (TRND) Program by the U.S. National Institutes of Health. The TRND Program is a...

  • Support for Orphan Diseases. Agres, Ted // Drug Discovery & Development;Jul2006, Vol. 9 Issue 7, p6 

    The article provides information on the U.S. National Institute of Health's Rare Diseases Clinical Research Network. The program, which has a $71 million five-year budget, is working with research consortia and patient advocacy groups that are conducting clinical trials and research on a variety...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics